SCHEMBL139079

SCHEMBL139079

C=CC(=O)OCCOP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
ESR1 P03372 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
CDC25A P30304 1/20 0.49
AGTR1 P30556 1/20 0.49
AKT1 P31749 1/20 0.49
ADRA1A P35348 1/20 0.49
KCNH2 Q12809 1/20 0.49
TSHR P16473 5/20 0.44
ALDH1A1 P00352 3/20 0.44
TP53 P04637 2/20 0.44
HIF1A Q16665 2/20 0.44
HSD17B10 Q99714 1/20 0.44
NR5A2 O00482 1/20 0.42
NR5A1 Q13285 1/20 0.42
HPGD P15428 1/20 0.41
ADRA1D P25100 1/20 0.41
PTAFR P25105 1/20 0.41
HTR1D P28221 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120088 0.96 ALDH1A1 (0.53) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL2117742 0.91 LMNA (0.54) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL2120223 0.91 LMNA (0.57) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL15389793 0.91 LMNA (0.47) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL2117747 0.90 LMNA (0.60) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL3627911 0.90 LMNA (0.60) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL2119799 0.90 LMNA (0.60) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL2120824 0.90 LMNA (0.60) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL2118513 0.90 LMNA (0.60) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL2120325 0.90 LMNA (0.60) SMN1; SMN2LMNAESR1ADORA3CDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 912 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12638614-B2 Method for making silicone hydrogel contact lenses ALCON INC. (CH) 2026-05-26 US claimed
CN-122057088-A Nickel-titanium alloy urethral stent with anti-calculus and antibacterial difunctional coating and preparation method thereof 海南百迈科医疗科技股份有限公司 2026-05-19 CN claimed
US-20260131506-A1 METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES ALCON INC (CH) 2026-05-14 US claimed
US-12595368-B2 UV/HEVL-filtering contact lenses ALCON INC. (CH) 2026-04-07 US claimed
EP-4713721-A1 UV/HEVL-FILTERING SILICONE HYDROGEL CONTACT LENSES Alcon Inc. (CH) 2026-03-25 EP claimed
EP-4707877-A2 METHOD FOR PRODUCING SILICON HYDROGEL CONTACT LENSES WITH CROSSLINKED HYDROPHILIC COATINGS THEREON Alcon Inc. (CH) 2026-03-11 EP claimed
US-12570784-B2 Method for making embedded hydrogel contact lenses ALCON INC. (CH) 2026-03-10 US claimed
EP-4514596-B1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES ALCON INC (CH) 2026-03-04 EP claimed
EP-3759528-B1 SILICONE HYDROGEL CONTACT LENSES ALCON INC (CH) 2026-03-04 EP claimed
EP-4703480-A1 SINGLE-STRANDED NUCLEIC ACID ADSORPTION INHIBITOR, NUCLEIC ACID SOLUTION, AND NUCLEIC ACID AMPLIFICATION METHOD NOF Corporation (JP) 2026-03-04 EP claimed
US-20100093846-A1 HYDROXAMATE COMPOSITIONS TYCO HEALTHCARE GROUP LP 2010-04-15 US claimed
US-20100081780-A1 DIOL (METH) ACRYLATE COMPOUND HAVING URETHANE BOND, METHOD FOR PRODUCING THE SAME, AND POLYMER THEREOF NOF CORPORATION (JP) 2010-04-01 US claimed
US-20100081779-A1 DIOL (METH) ACRYLATE COMPOUND HAVING URETHANE BOND, METHOD FOR PRODUCING THE SAME, AND POLYMER THEREOF NOF CORPORATION (JP) 2010-04-01 US claimed
EP-2160192-A1 ANTIMICROBIAL MATERIALS AND COATINGS Tyco Healthcare Group LP (US) 2010-03-10 EP claimed
EP-2160193-A1 FURANONE COPOLYMERS Tyco Healthcare Group LP (US) 2010-03-10 EP claimed
EP-2120824-A1 COATING COMPOSITIONS Tyco Healthcare Group LP (US) 2009-11-25 EP claimed
WO-2008144248-A1 FURANONE COPOLYMERS TYCO HEALTHCARE GROUP LP (US) 2008-11-27 WO claimed
WO-2008144247-A1 ANTIMICROBIAL MATERIALS AND COATINGS TYCO HEALTHCARE GROUP LP (US) 2008-11-27 WO claimed
WO-2008143654-A1 COATING COMPOSITIONS TYCO HEALTHCARE GROUP LP (US) 2008-11-27 WO claimed
WO-2003040218-A1 POROUS POLYMER FILMS POLYMERAT PTY LTD (AU) 2003-05-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595368-B2 UV/HEVL-filtering contact lenses UACA, HSPA4L, RAD54L SMN1; SMN2 4624/4885LMNA 2948/4885ESR1 2368/4885
US-12570784-B2 Method for making embedded hydrogel contact lenses CRYAB, CRYZ, CRYAA SMN1; SMN2 4766/4885LMNA 219/4885ESR1 4484/4885
US-12638614-B2 Method for making silicone hydrogel contact lenses SMCHD1, CRYAA, CRYZ SMN1; SMN2 4315/4885LMNA 1330/4885ESR1 3419/4885
US-20100093846-A1 HYDROXAMATE COMPOSITIONS HCAR3, ABHD16A, PLA2G2C SMN1; SMN2 3890/4885LMNA 3232/4885ESR1 2634/4885
US-20260131506-A1 METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES CRYZ, CRYAB, CRYAA SMN1; SMN2 4239/4885LMNA 1320/4885ESR1 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.